Celera Genomics Licenses Cancer Targets from Proteomics Effort to Genentech

Sep 28, 2004

NEW YORK, Sept. 28 (GenomeWeb News) - Celera Genomics and Genentech have signed a multi-year agreement to develop new cancer drugs based on targets derived from Celera's proteomics platform, Celera said today.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Now You Can Read Them, Now You Can't

What happens to scientific papers when certain journals are no longer published? Some scientists are trying to make sure they don't disappear forever.

The Mouths of Heavy Drinkers Are Disgusting

A study in Microbiome finds that heavy drinkers have an unhealthy mix of bacteria in their mouths.

For Health or For Fun?

Doctors and patients are still trying to figure out what role at-home genetic testing should play in healthcare, Newsweek says.

This Week in Genome Research

In Genome Research this week, mismatch repair deficiency in C. elegans, retracing transcriptions start site evolution in the human genome, and more.

Main menu